These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12010415)

  • 1. Haemophilia 2002: emerging risks of treatment.
    Evatt BL; Farrugia A; Shapiro AD; Wilde JT
    Haemophilia; 2002 May; 8(3):221-9. PubMed ID: 12010415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging and receding risks of therapeutic regimens for haemophilia.
    Farrugia A; Manno CS; Evatt BL
    Haemophilia; 2004 Oct; 10 Suppl 4():47-54. PubMed ID: 15479372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.
    Ludlam CA
    Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779
    [No Abstract]   [Full Text] [Related]  

  • 5. Haemophilia.
    Cahill MR; Colvin BT
    Postgrad Med J; 1997 Apr; 73(858):201-6. PubMed ID: 9156121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 7. Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
    Aouba A; Harroche A; Frenzel L; Torchet MF; Rothschild C; François I; Mamzer-Bruneel MF
    Haemophilia; 2015 Jan; 21(1):27-33. PubMed ID: 25545300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia.
    Baxter T; Black D; Birks D
    Lancet; 1998 Feb; 351(9102):600-1. PubMed ID: 9492811
    [No Abstract]   [Full Text] [Related]  

  • 10. Haemophilia care then, now and in the future.
    Oldenburg J; Dolan G; Lemm G
    Haemophilia; 2009 Jan; 15 Suppl 1():2-7. PubMed ID: 19125934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prions and haemophilia: assessment of risk.
    Evatt BL
    Haemophilia; 1998 Jul; 4(4):628-33. PubMed ID: 9873805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of protease inhibitors in HIV-infected haemophilia patients.
    Merry C; McMahon C; Ryan M; O'Shea E; Mulcahy F; Smith OP
    Br J Haematol; 1998 Jun; 101(3):475-9. PubMed ID: 9633889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical issues in inhibitors.
    Astermark J; Santagostino E; Keith Hoots W
    Haemophilia; 2010 Jul; 16 Suppl 5():54-60. PubMed ID: 20590857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives.
    Farrugia A
    Haemophilia; 2002 May; 8(3):230-5. PubMed ID: 12010416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion-transmitted disease.
    Lee CA
    Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome measures in haemophilia: a systematic review.
    Boehlen F; Graf L; Berntorp E
    Eur J Haematol Suppl; 2014 Aug; 76():2-15. PubMed ID: 24957102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective audit of patients with haemophilia: bleeding episodes and management.
    Alexander M; Barnes C; Barnett P
    J Paediatr Child Health; 2012 Feb; 48(2):177-9. PubMed ID: 21564382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events in the prophylaxis of haemophilia.
    Giangrande PL
    Haemophilia; 2003 May; 9 Suppl 1():50-4; discussion 55-6. PubMed ID: 12709038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.